ARTICLE | Clinical News
BGB-3111: Ph III started
January 27, 2017 4:35 AM UTC
BeiGene began an international Phase III trial of 160 mg oral BGB-3111 twice daily in about 170 relapsed or refractory or treatment-naïve patients. The trial will compare BGB-3111 vs. once-daily 420 m...
BCIQ Company Profiles
BCIQ Target Profiles